

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

HEALTHCARE & LIFE SCIENCES FUND AT A GLANCE

Manager: Dr. Finny Kuruvilla

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A diversified mutual fund representing our "best ideas" for long-term capital appreciation in the healthcare and life sciences sectors (≥80%). Concentrates investments in the drug-related industries (≥25%). May invest in illiquid securities (≤15%).

Benchmarks: S&P 500 Total Return Index, S&P Biotechnology Select Industry Index

Morningstar Category: US Fund Health

Lipper Category: Health/Biotech

Net Assets: \$1.71 billion

Inception Date: December 27, 2012

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

REVIEW

The Eventide Healthcare and Life Sciences Fund (Class N) posted a total return of 2.28% for the third quarter of 2020, compared with the S&P 500 Total Return Index of 8.93% and the S&P Biotechnology Select Industry Index total return of -0.55%. The Fund (Class N) posted a total return of 57.19% for the 12 months ending 9/30/2020 compared to the S&P 500 Total Return Index of 15.15% and the S&P Biotechnology Select Industry Index of 46.22%. The Fund underperformed its benchmark due to not owning some of the attractive COVID-19 vaccine stocks, as well as security selection.

CONTRIBUTORS

In the third quarter of 2020, the largest positive contributors to performance were Momenta Pharmaceuticals, MyoKardia Inc, Trillium Therapeutics Inc, Mirati Therapeutics Inc, and Annexon Inc. Momenta was acquired at a significant premium. Myokardia had a successful Phase 3 trial. Trillium Therapeutics disclosed positive clinical trial progress as well as an equity stake from Pfizer. Mirati Therapeutics benefited from incremental positive data from Amgen on their KRAS gene program, which is a significant value driver for the company. Annexon has benefited from interest in the company's mechanism of action and platform.

Top Five Contributors ¹ (%)					Q3 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Momenta Pharmaceuticals	MNTA	Biotechnology	1.52	1.84	56.63
MyoKardia Inc	MYOK	Biotechnology	4.03	1.47	41.10
Trillium Therapeutics Inc	TRIL	Biotechnology	1.68	0.98	75.78
Mirati Therapeutics Inc	MRTX	Biotechnology	2.51	0.95	45.44
Annexon Inc	ANNX	Biotechnology	0.95	0.81	141.27

DETRACTORS

In the third quarter of 2020, the largest negative detractors to performance were Kala Pharmaceuticals, BELLUS Health Inc, Sarepta Therapeutics Inc, Satsuma Pharmaceuticals Inc, and Karuna Therapeutics Inc. Kala Pharmaceuticals' sub-par performance is due to commercial headwinds the company has been facing and is quite typical of performance of biotech companies in the early stages of commercialization. Bellus Health failed in a Phase 2 study. Sarepta's lack of recent valuation-inflecting events and positive news from competitor Pfizer Inc for their Duchenne muscular dystrophy gene therapy has pressured the stock. Satsuma had a failed Phase 3 study. Karuna's lack of recent valuation-inflecting events has pressured the stock.

Top Five Detractors ¹ (%)					Q3 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Kala Pharmaceuticals	KALA	Biotechnology	1.96	-0.63	-28.64
BELLUS Health Inc	BLU	Biotechnology	0.07	-0.65	-68.60
Sarepta Therapeutics Inc	SRPT	Biotechnology	5.18	-0.67	-12.42
Satsuma Pharmaceuticals Inc	STSA	Biotechnology	1.20	-1.42	-83.21
Karuna Therapeutics Inc	KRTX	Biotechnology	4.76	-1.84	-30.63

MACRO COMMENTARY AND OUTLOOK

The third quarter was a boom for biotechnology and health care. 47% of the 81 IPOs during 3Q20 were health care startups, with notable prominence from telehealth companies and biotechnology. In addition, the aftermarket performance of those IPOs helped induce what John Maynard Keynes termed "animal spirits" among those sitting on the sidelines, further increasing equity demand. This demand has sometimes been indiscriminate. While COVID-19 companies enjoyed special attention, we continue to fear that those companies may remain significantly overvalued. Our thesis is that in this environment of lofty expectations regarding equity exuberance, caution is warranted. A disciplined approach to valuation is particularly important in this period where gains can quickly be erased. While we believe that biotechnology will be one of the great secular trends of the century, this of course does not negate periods of excessively positive (or negative) sentiment in the space. Besides valuation concerns, the market will need greater clarity from the elections to more efficiently price equities into 2021 and beyond. As a safe and effective vaccine hopefully

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

comes to the foreground, and the elections occur in November, the fourth quarter's catalysts will be especially important for healthcare. We believe that active management will help through such a challenging environment.

Trailing Returns ³	30 Sep 2020				
Eventide Healthcare & Life Sciences Fund	YTD	1-year	3-Year ⁴	5-Year ⁴	Since Inception ⁴
Class N	7.39	57.19	21.10	19.43	23.01
Class A without load	7.36	57.14	21.00	19.35	22.91
Class A with 5.75% load ⁵	1.19	48.09	18.63	17.94	21.98
Class C	6.73	55.93	20.11	18.47	22.01
Class I	7.55	57.51	21.34	19.67	23.24
Benchmarks					
S&P 500 Total Return Index ⁶	5.57	15.15	12.28	14.15	14.08
S&P Biotechnology Select Industry Index ⁶	17.08	46.22	8.94	12.54	19.03

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Healthcare & Life Sciences Fund total annual fund operating expenses: Class A: 1.54%; Class C: 2.29%; Class I: 1.29%; Class N: 1.49%.

1. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
2. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
4. Performance figures for periods greater than 1 year are annualized. Annualized since inception figures use an inception date of 12/27/2012.
5. In the case of investments at or above the \$1 million breakpoint (where you do not pay an initial sales charge), a 1.00% contingent deferred sales charge ("CDSC") may be assessed on shares redeemed within eighteen months of purchase. The CDSC for these Class A shares is based on the NAV at the time of purchase. The holding period for the CDSC begins on the day you buy your shares. Some intermediaries may waive or discount the CDSC under certain circumstances.
6. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index.

The opinions expressed herein are those of the Fund's portfolio management team as of 9/30/2020 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.